Pharmaco - Press Releases

Date	Title	Company
10-Oct-2023	Life sciences leaders unite to condemn radical plans to rewrite medicines scheme	British Pharmaceutical Industry (ABPI)
10-Oct-2023	Brandon Capital Joins AstronauTx’ £48 million ($61 million) Series A Financing to Create New Treatments for Alzheimer’s disease	Brandon Capital
10-Oct-2023	Novotech Secures Consecutive Frost & Sullivan CRO Company of the Year Award	Novotech
10-Oct-2023	LYNPARZA (OLAPARIB) ACCEPTED FOR USE IN SCOTLAND AS ADJUVANT TREATMENT FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE HIGH RISK EARLY BREAST CANCER	AstraZeneca
10-Oct-2023	Copley launches a new blog for the pharmaceutical testing community	Copley Scientific
10-Oct-2023	Strong partners for a sustainable future in the pharmaceutical industry: Perlen Packaging and Etimex Primary Packaging join forces	Perlen Packaging
10-Oct-2023	Elsevier launches new PharmaPendium, empowering pharma companies to bring novel drugs to market faster and increase success of regulatory submissions	Elsevier
10-Oct-2023	Cryoport and Cell and Gene Therapy Catapult Announce Strategic Collaboration at Stevenage Manufacturing Innovation Centre for Advancement of Cell and Gene Therapies	Cryoport, Inc
10-Oct-2023	Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225	Eckert & Ziegler Strahlen- und Medizintechnik AG
10-Oct-2023	Roche’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies	Roche
10-Oct-2023	PM Society Awards 2024 Open for Entries!	PM Society
10-Oct-2023	DLOC Biosystems chooses Discovery Park for new biology facility to develop organ-on-a-chip technology	Sciad Newswire
10-Oct-2023	SYNLAB launches revolutionary bipolar disorder diagnostic test: myEDIT-B	SYNLAB AG
10-Oct-2023	DEFENCE ANNOUNCES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUM® AS AN ANTI-CANCER MOLECULE IN THE JOURNAL OF CANCER SCIENCE	Defence Therapeutics Inc.
10-Oct-2023	Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States	Formycon AG
10-Oct-2023	Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)	Cosmo Pharmaceuticals N.V.
10-Oct-2023	Relief Therapeutics Announces that more than 400,000 of its ADRs are currently outstanding and that, as a result, the Company has achieved an Important NASDAQ Initial Listing Milestone	Relief Therapeutics Holding SA
09-Oct-2023	IGEA Pharma N.V.: IGEA to update on RBCARE business combination	IGEA Pharma N.V.
09-Oct-2023	Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria	Newron Pharmaceuticals S.p.A.
06-Oct-2023	SCHOTT Pharma IPO: Early termination of stabilization period and full exercise of the Greenshoe Option	SCHOTT Pharma AG & Co. KGaA